FRIDAY, DECEMBER 13 BREAKOUT SESSION

---

Racial Disparities in Advanced Prostate Cancer

Sanoj Punnen, MD

Genomic Landscape of Prostate Cancer and Implications for Therapy selection

Gennady Bratslavsky, MD

Role of Theranostics and PARP Inhibitors

Cora Sternberg (Prof.), MD, FACP

Updates in Neoadjuvant Therapy Trials for Prostate Cancer

Brian Chapin, MD

Treatment De-Escalation in Metastatic Hormone-Sensitive PCa

Che-Kai Tsao, MD, MS

Transaltional Analyses from STAMPEDE inc Expression Profiling (presented ESMO24) and Also Long Term Risk of Fractures (ESMO 23 and EAU 23) 

Nick James (Prof)., MBBS, PhD

Advanced Staged Pca (Research)

Christina Jamieson, MD

Q&A

Pushing the Limits of Focal Therapy: How Much Pattern 4 is Acceptable?

Art Rastinehad, DO

Why Cryotherapy is My Preferred Modality for Prostate Ablation

Michael Gorin, MD

Q&A

Break / Visit Exhibits / Visit Abstract Session

RaPiDS in Kidney Cancer: Advancements in Drug Sensitivity Assessment and Future Directions

Ben Hopkins, PhD

Exploitation of Metabolic Pathways for Therapeutic Targeting of Advanced Renal Cancer

Roberto Pili, MD

Catalytic Inhibitors of Protein Phosphatases: A Path to Precision Kidney Cancer Therapy

Mehdi Mollapour, PhD

Advances in Kidney Cancer: Quantitative Ultrasound Innovations and Applications

Jonathan Mamou (Prof.), PhD

Q&A

Return to Main Session